Bone health management of Australian breast cancer survivors receiving hormonal therapy

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Breast cancer survivors are at risk of bone loss due to hormonal treatment. We conducted a case note audit to investigate patterns of care and adherence to guidelines for initial management of risk of bone loss in 42 women receiving hormonal therapy. All those receiving aromatase inhibitors (n = 14) and 10 on tamoxifen had a bone density assessment. Eleven (26%) women had osteopenia and four (9.5%) osteoporosis. Management was variable and not always aligned with the guidelines.

Original languageEnglish
Pages (from-to)1182-1185
Number of pages4
JournalInternal Medicine Journal
Volume45
Issue number11
DOIs
Publication statusPublished - Nov 2015

Keywords

  • Aromatase inhibitors
  • Bone
  • Breast cancer
  • Osteoporosis

Fingerprint

Dive into the research topics of 'Bone health management of Australian breast cancer survivors receiving hormonal therapy'. Together they form a unique fingerprint.

Cite this